Section of Ophthalmology, Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Head Neck. 2011 May;33(5):610-4. doi: 10.1002/hed.21498. Epub 2010 Sep 7.
The purpose of this study was to evaluate the frequencies of various types of orbital lesions seen at a comprehensive cancer center in the United States.
In this retrospective case series, we reviewed the medical records of 268 consecutive patients referred to our orbital oncology service for evaluation of an orbital mass between November 1998 and February 2009. Each orbital lesion was documented by CT and/or MRI, and in most cases diagnosis was established with a tissue biopsy. Patients who were seen for second opinions and had inadequate follow-up data were excluded, as were patients with thyroid eye disease or orbital hemorrhage.
The study included 134 men and 134 women aged 1 to 89 years at diagnosis (median, 55 years). Follow-up ranged from 0.06 to 192 months (median, 15 months). Of the tumors, 171 (64%) were primary orbital, 69 (26%) were secondary orbital, and 28 (10%) were metastatic tumors. Lesion types were as follows: secondary orbital tumors, 69 (26%); lymphoproliferative lesions, 68 (25%); metastases, 28 (10%); epithelial lacrimal gland tumors, 27 (10%); inflammatory conditions, 21 (8%); vascular lesions, 20 (7%); mesenchymal tumors, 18 (7%); optic nerve and nerve sheath tumors, 7 (3%); peripheral nerve tumors, 3 (1%); histiocytic lesions, 3 (1%); cystic lesions, 3 (1%); and other lesions, 1 (<1%). The most common histopathologic diagnoses were lymphoma, 50 cases (19%); orbital extension of sinus tumor, 25 (9%); lacrimal gland adenoid cystic carcinoma, 18 (7%); cavernous hemangioma, 15 (6%); orbital extension of brain tumor, 14 (5%); idiopathic orbital inflammation, 14 (5%); plasmacytoma, 8 (3%); reactive lymphoid hyperplasia, 7 (3%); metastatic breast cancer, 7 (3%); orbital extension of ocular adnexal basal cell carcinoma, 7 (3%); orbital extension of ocular adnexal melanoma, 6 (2%), rhabdomyosarcoma, 6 (2%); metastatic gastrointestinal cancer, 5 (2%); sarcoidosis, 5 (2%); and other less common lesions. Forty-two lesions (16%) were intraconal, and 226 (84%) were extraconal. There were 169 (63%) malignant tumors and 99 (37%) were benign tumors. The rate of malignant lesions was 65% in children and 63% in adults (≥18 years). Malignant conditions encountered at a higher rate than previously reported included lymphoma (19% vs 8% to 13%), secondary orbital tumors (26% vs 13% to 20%), orbital metastases (10% vs 2% to 7%), and malignant epithelial lacrimal gland tumors (9% vs 2% to 3%).
Our findings highlight the distinctive nature of the orbital oncology experience at a comprehensive cancer center. We found higher than previously reported rates of malignant tumors (63% of all tumors), particularly secondary tumors, malignant epithelial lacrimal gland tumors, and orbital metastases.
本研究旨在评估在美国一家综合性癌症中心中所见各种类型眶部病变的频率。
在这项回顾性病例系列研究中,我们复习了 1998 年 11 月至 2009 年 2 月间因眶部肿块就诊于我们眼眶肿瘤服务的 268 例连续患者的病历。每例眶部病变均通过 CT 和/或 MRI 进行记录,大多数病例通过组织活检确定诊断。我们排除了因第二次就诊且随访资料不充分、甲状腺眼病或眶部出血的患者。
本研究纳入了 134 名男性和 134 名女性患者,其诊断时的年龄为 1 至 89 岁(中位数,55 岁)。随访时间为 0.06 至 192 个月(中位数,15 个月)。肿瘤中,171 例(64%)为原发性眶部病变,69 例(26%)为继发性眶部病变,28 例(10%)为转移性肿瘤。病变类型如下:继发性眶部病变,69 例(26%);淋巴增生性病变,68 例(25%);转移,28 例(10%);上皮性泪腺肿瘤,27 例(10%);炎症性疾病,21 例(8%);血管性病变,20 例(7%);间叶性肿瘤,18 例(7%);视神经和神经鞘肿瘤,7 例(3%);周围神经肿瘤,3 例(1%);组织细胞病变,3 例(1%);囊性病变,3 例(1%);和其他病变,1 例(<1%)。最常见的组织病理学诊断为淋巴瘤,50 例(19%);鼻窦肿瘤的眶部扩展,25 例(9%);泪腺腺样囊性癌,18 例(7%);海绵状血管瘤,15 例(6%);脑肿瘤的眶部扩展,14 例(5%);特发性眶部炎症,14 例(5%);浆细胞瘤,8 例(3%);反应性淋巴组织增生,7 例(3%);转移性乳腺癌,7 例(3%);眼附属器基底细胞癌的眶部扩展,7 例(3%);眼附属器黑色素瘤的眶部扩展,6 例(2%),横纹肌肉瘤,6 例(2%);转移性胃肠道癌,5 例(2%);结节病,5 例(2%);和其他较少见的病变。42 例病变(16%)位于眶内,226 例(84%)位于眶外。169 例(63%)为恶性肿瘤,99 例(37%)为良性肿瘤。儿童恶性病变的发生率为 65%,成人(≥18 岁)为 63%。与既往报道相比发生率更高的恶性疾病包括淋巴瘤(19%比 8%至 13%)、继发性眶部病变(26%比 13%至 20%)、眶部转移(10%比 2%至 7%)和恶性上皮性泪腺肿瘤(9%比 2%至 3%)。
我们的发现强调了综合性癌症中心的眼眶肿瘤学经验的独特性质。我们发现恶性肿瘤(所有肿瘤的 63%),特别是继发性肿瘤、恶性上皮性泪腺肿瘤和眶部转移的发生率高于既往报道。